Idioma:

Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection

Mitchell, Julie L ; Pollara, Justin ; Dietze, Kenneth ; Edwards, R Whitney ; Nohara, Junsuke ; N'guessan, Kombo F ; Zemil, Michelle ; Buranapraditkun, Supranee ; Takata, Hiroshi ; Li, Yifan ; Muir, Roshell ; Kroon, Eugene ; Pinyakorn, Suteeraporn ; Jha, Shalini ; Manasnayakorn, Sopark ; Chottanapund, Suthat ; Thantiworasit, Pattarawat ; Prueksakaew, Peeriya ; Ratnaratorn, Nisakorn ; Nuntapinit, Bessara ; Fox, Lawrence ; Tovanabutra, Sodsai ; Paquin-Proulx, Dominic ; Wieczorek, Lindsay ; Polonis, Victoria R ; Maldarelli, Frank ; Haddad, Elias K ; Phanuphak, Praphan ; Sacdalan, Carlo P ; Rolland, Morgane ; Phanuphak, Nittaya ; Ananworanich, Jintanat ; Vasan, Sandhya ; Ferrari, Guido ; Trautmann, Lydie

The Journal of clinical investigation, 2022-01, Vol.132 (1), p.1-11 [Revista revisada por pares]

United States: American Society for Clinical Investigation

Texto completo disponible

Citas Citado por

Acciones

Título:
Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection
Autor: Mitchell, Julie L ; Pollara, Justin ; Dietze, Kenneth ; Edwards, R Whitney ; Nohara, Junsuke ; N'guessan, Kombo F ; Zemil, Michelle ; Buranapraditkun, Supranee ; Takata, Hiroshi ; Li, Yifan ; Muir, Roshell ; Kroon, Eugene ; Pinyakorn, Suteeraporn ; Jha, Shalini ; Manasnayakorn, Sopark ; Chottanapund, Suthat ; Thantiworasit, Pattarawat ; Prueksakaew, Peeriya ; Ratnaratorn, Nisakorn ; Nuntapinit, Bessara ; Fox, Lawrence ; Tovanabutra, Sodsai ; Paquin-Proulx, Dominic ; Wieczorek, Lindsay ; Polonis, Victoria R ; Maldarelli, Frank ; Haddad, Elias K ; Phanuphak, Praphan ; Sacdalan, Carlo P ; Rolland, Morgane ; Phanuphak, Nittaya ; Ananworanich, Jintanat ; Vasan, Sandhya ; Ferrari, Guido ; Trautmann, Lydie
Materias: Acute Disease ; Adult ; AIDS/HIV ; Anti-Retroviral Agents - administration & dosage ; Antibodies ; Antibody-dependent cell-mediated cytotoxicity ; Antigens ; Antiretroviral drugs ; Antiretroviral therapy ; Antiviral agents ; B cells ; Biomedical research ; Cell Line ; Cytotoxicity ; Development and progression ; Drug therapy ; Female ; Health aspects ; Highly active antiretroviral therapy ; HIV ; HIV (Viruses) ; HIV antibodies ; HIV Antibodies - blood ; HIV infection ; HIV Infections - blood ; HIV Infections - drug therapy ; HIV-1 - metabolism ; Human immunodeficiency virus ; Humans ; Identification and classification ; Immune response ; Immunology ; Infections ; Male ; Mutation ; Observations ; Patient outcomes ; Plasma ; Protein seeding ; Therapeutic applications ; Viremia ; Viremia - blood ; Viremia - drug therapy ; Virus diseases
Es parte de: The Journal of clinical investigation, 2022-01, Vol.132 (1), p.1-11
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Authorship note: GF and LT are co–senior authors.
Descripción: Early initiation of antiretroviral therapy (ART) in acute HIV infection (AHI) is effective at limiting seeding of the HIV viral reservoir, but little is known about how the resultant decreased antigen load affects long-term Ab development after ART. We report here that Env-specific plasma antibody (Ab) levels and Ab-dependent cellular cytotoxicity (ADCC) increased during the first 24 weeks of ART and correlated with Ab levels persisting after 48 weeks of ART. Participants treated in AHI stage 1 had lower Env-specific Ab levels and ADCC activity on ART than did those treated later. Importantly, participants who initiated ART after peak viremia in AHI developed elevated cross-clade ADCC responses that were detectable 1 year after ART initiation, even though clinically undetectable viremia was reached by 24 weeks. These data suggest that there is more germinal center (GC) activity in the later stages of AHI and that Ab development continues in the absence of detectable viremia during the first year of suppressive ART. The development of therapeutic interventions that can enhance earlier development of GCs in AHI and Abs after ART initiation could provide important protection against the viral reservoir that is seeded in individuals treated early in the disease.
Editor: United States: American Society for Clinical Investigation
Idioma: Inglés

Enlaces

View this record in MEDLINE/PubMed

Volver a la lista de resultados

Resultado 1 Siguiente Ir a la siguiente página

Realización: Logos de Redes Sociales:

Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection

United States: American Society for Clinical Investigation

Buscando en bases de datos remotas, por favor espere